Answers are grounded in this paper and cite their sources.
Our study suggests that patients who have active inflammation with seemingly adequate serum anti-TNF levels have increased levels of specific inflammatory pathways that may serve as biomarkers of nonresponse as well as potential targets of therapy in anti-TNF nonresponders.
No takes yet. Share an insight, caveat, or question.
Yarur et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: